Pyxis Oncology (PYXS) filed a shelf registration statement with the US Securities and Exchange Commission on Wednesday for the potential sale of up to $350 million in securities, to be offered from time to time.
The filing covers common stock, preferred stock, warrants, debt securities, units, and rights to purchase common stock, preferred stock, debt securities or units.
Pyxis said it intends to use the net proceeds for general corporate purposes, including working capital, operating expenses and capital expenditures, as well as to acquire or invest in businesses and products that are complementary to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.